Document is current
Any future updates will be listed below
-
Authors
Gustafsson, Karin
Isaev, Sergey
Mirsanaye, Kamdin
Hofmann, Johanna https://orcid.org/0009-0009-9382-7800
Kooshesh, Kameron A.
Baryawno, Ninib https://orcid.org/0000-0001-6054-4163
Kiem, Anna
Severe, Nicolas
Zhao, Ting
Scadden, Elizabeth W.
Spencer, Joel A. https://orcid.org/0000-0002-4013-8763
Burns, Christian https://orcid.org/0000-0003-2090-0252
Akilan, Kumaran
Barkas, Nikolaos
Gessessew, Hayalneh
Kokkaliaris, Konstantinos D. https://orcid.org/0000-0002-9952-3463
Lin, Charles P.
Kharchenko, Peter V. https://orcid.org/0000-0002-6036-5875
Scadden, David T. https://orcid.org/0000-0001-9821-7133
-
Funding
Funding for this research was provided by:
Tracey and Craig A. Huff Harvard Stem Cell Institute Research Support Fund and the Gerald and Darlene Jordan Professorship of Medicine
Vetenskapsrådet
Natural Sciences and Engineering Research Council of Canada (NSERC) Postdoctoral Fellowship
- License Information
-
More Information
Article History
Received: 25 June 2023
Accepted: 12 September 2025
First Online: 30 October 2025
Competing interests
: D.T.S. is a director and shareholder of Agios Therapeutics and Editas Medicines; a shareholder and founder of Fate Therapeutics and Stratus Therapeutics; a director, founder and shareholder of Lightning Biotechnology; a director of Sonata Theraepeutics; and a consultant for Simcere Zaiming and VCanBio. D.T.S. and K.G. are inventors of patent US20220143099A1. P.V.K. serves on the scientific advisory board for Celsius Therapeutics, Inc. and Biomage, Inc. The other authors declare no competing interests.
